PROVIDES DATA NEEDED BY FDA MEDICAL
OFFICERS IN DETERMININ WHETHER AND HOW A PROPOSED NEW DRUG MAY BE
TESTED FOR SAFETY AND EFFECTIVENESS. THIS REVISION ADDS THE
INFORMATION COLLECTION REQUIREMENTS OF THE "TREATMENT USE OF AN
INVESTIGATIONAL NEW DRUG" WHI AFFECTS THE AVAILABILITY OF
UNAPPROVED DRUGS FOR USE IN THE TREATMENT OF LIFE THREATENING
DISEASES FOR WHICH THERE IS NO KNOWN EFFECTIVE
On behalf of this Federal agency, I certify that
the collection of information encompassed by this request complies
with 5 CFR 1320.9 and the related provisions of 5 CFR
1320.8(b)(3).
The following is a summary of the topics, regarding
the proposed collection of information, that the certification
covers:
(i) Why the information is being collected;
(ii) Use of information;
(iii) Burden estimate;
(iv) Nature of response (voluntary, required for a
benefit, or mandatory);
(v) Nature and extent of confidentiality; and
(vi) Need to display currently valid OMB control
number;
If you are unable to certify compliance with any of
these provisions, identify the item by leaving the box unchecked
and explain the reason in the Supporting Statement.